Telix Locks In Phase 3 BiPASS Enrollment and an FDA Pathway — Nine Days Ahead of a PDUFA Date

Telix Pharmaceuticals (NASDAQ: TLX; ASX: TLX) completed enrollment in its Phase 3 BiPASS study and secured FDA alignment on a New Drug Application pathway, sending shares up 5.25% to $11.42 in Wednesday premarket trading after a $10.85 close. The move stands out because enrollment completions rarely move stocks. This one did, and the reason has less to do with the trial itself than with what sits nine days ahead of it.

Key Points

• Telix (TLX) finished enrolling 350 patients in the Phase 3 BiPASS study across U.S. and Australian sites.
• BiPASS tests 68Ga-PSMA-PET imaging alongside MRI to detect prostate cancer before biopsy, a new setting for the technology.
• The FDA engaged positively on an NDA pathway, which would support reimbursement as a new product rather than an off-label extension.
• More than 3 million prostate biopsies occur globally each year, and up to 75% come back negative.
• Earlier PRIMARY and PRIMARY2 studies cut unnecessary biopsies by roughly 50% using the same imaging combination.
• Separately, Telix faces a September 11 FDA target action date for Pixclara (TLX101-Px) in recurrent or progressive glioma.

What BiPASS actually tests

Telix already sells PSMA-PET imaging agents. Illuccix® carries FDA approval and reaches 22 countries, while Gozellix® followed it to market. Clinicians currently use both to stage prostate cancer and to restage it at recurrence — in other words, after a diagnosis exists.

BiPASS moves the technology upstream. The prospective, open-label study asks whether combining 68Ga-PSMA-PET with MRI can identify clinically significant prostate cancer before a man undergoes biopsy, and whether that combination safely spares patients the procedure altogether.

Consequently, the addressable problem is large and unusually well documented. Globally, more than 3 million prostate biopsies happen annually, and as many as three-quarters return negative. Prior work in the PRIMARY and PRIMARY2 studies suggested the imaging pair could eliminate roughly half of them.

Chief Medical Officer Dr. David N. Cade noted that recruitment finished quickly, “reflecting strong enthusiasm from clinicians and patients.” Principal investigators Professor Louise Emmett of St Vincent’s Hospital and Dr. Brian Mazzarella of Urology America echoed the clinical case.

Why the FDA alignment matters more than the enrollment

Here is the part investors should isolate. Enrollment completion is a process milestone. It carries no efficacy data, no readout date, and no approval. Telix disclosed no timeline for topline results.

The NDA pathway alignment is different. Pursuing a new drug application — rather than folding pre-biopsy use into existing labels — positions the indication as a separately reimbursable product. In diagnostics, reimbursement determines whether clinical adoption translates into revenue. Therefore the regulatory framing, not the enrollment count, is what re-rates the opportunity.

The catalyst that actually explains the move

Telix carries a $3.69 billion market capitalization and trades in a 52-week range of $6.28 to $12.48, meaning Wednesday’s premarket print sits near the upper end. Momentum matters here.

On September 11, the FDA faces a target action date for Pixclara (TLX101-Px), an imaging agent for characterizing recurrent or progressive glioma in adult and pediatric patients. Telix resubmitted that application on March 13, 2026, and the candidate holds Orphan Drug and Fast Track designations.

Meanwhile, the therapeutic pipeline continues to build behind the imaging franchise: TLX591-Tx (177Lu rosopatamab) in prostate cancer, TLX101-Tx (131I-iodofalan) in glioblastoma, and TLX250-Tx (177Lu girentuximab) in kidney cancer.

For investors tracking commercial-stage radiopharmaceutical names, the sequence is the story. A widened regulatory pathway landed first. A binary approval decision lands next week.